Increasing access to hematopoietic cell transplantation in Latin America: results of the 2018 LABMT activity survey and trends since 2012

Correa, Cinthya; González-Ramella, Óscar; Basquiera, Ana Lisa; Arcuri, Leonardo Javier; Puga, Bárbara; Hernández, Calixto; León, Andrés Gómez‐De; Mendoza, Ninotchka; Karduss-Urueta, Amado J; Jaimovich, Gregorio; Greinix, Hildegard; Koh, Mickey; Aljurf, Mahmoud; Iida, Minako; Saber, Wael; Atsuta, Yoshiko; Galeano, Sebastián; Baldomero, Helen; Baena, Rosio; Rosales, Carmen; Chávez, Marlene; Maldonado, Bella; Frutos, Cristóbal; Aranda, Lourdes; Díaz, Lilián; Hernández, Marcos; Seber, Adriana; Karduss, Amado; Martínez-Rolón, Juliana; Bonfim, Carmem; Niederwieser, Dietger

doi:10.1038/s41409-022-01630-9

Cited by 12 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of transplants in Latin America has increased in the last few years; however, there is still a low transplant rate of just 77 procedures for every ten million persons, while this indicator is almost 500 in North America. The density of teams is 1.6 for 10 million, almost six times less than in Europe or North America 35 .…”

Section: Labmt Perspectivementioning

confidence: 90%

Fostering next generation transplant physicians

2024

BCT

View full text Add to dashboard Cite

As opposed to the rapid expansion of hematopoietic cell transplantation (HCT) and other cellular therapies (CT), we are now facing a global shortage of transplant physicians and other professionals to support the activity of HCT/CT. To overcome this obstacle, a variety of approaches are now being undertaken in four international HCT societies. This article aims to share their current attempts to foster the next generation of transplant physicians and allied professionals needed to secure the continued global growth of HCT/CT.

show abstract

Section: Labmt Perspectivementioning

confidence: 90%

Fostering next generation transplant physicians

2024

BCT

View full text Add to dashboard Cite

show abstract

“…HSCT is formally available in Mexico since 1995, and currently, around 15 centers have experienced and well-established programs in public and private hospitals, with variable capacity to perform autologous and allogeneic procedures from compatible related and unrelated, cord blood, or haploidentical donors ( 8 , 56 ). There are several reports of the Mexican HSCT experience, which can be comparable with the success in other developing and developed countries ( 57 ).…”

Section: Overcoming Limitations To Enhance Car-t Cell Therapy Accessi...mentioning

confidence: 99%

Childhood leukemias in Mexico: towards implementing CAR-T cell therapy programs

Bustamante-Ogando,

Hernández-López,

Galván-Díaz

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Leukemias are the most common type of pediatric cancer around the world. Prognosis has improved during the last decades, and many patients are cured with conventional treatment as chemotherapy; however, many patients still present with a refractory disease requiring additional treatments, including hematopoietic stem cell transplantation. Immunotherapy with monoclonal antibodies or cellular therapy is a promising strategy for treating refractory or relapsed hematological malignancies. Particularly, CAR-T cells have shown clinical efficacy in clinical trials, and different products are now commercially approved by regulatory agencies in the USA and Europe. Many challenges still need to be solved to improve and optimize the potential of these therapies worldwide. Global access to cell therapy is a significant concern, and different strategies are being explored in the middle- and low-income countries. In Mexico, leukemias represent around 50% of total cancer diagnosed in pediatric patients, and the rate of relapsed or refractory disease is higher than reported in other countries, a multi-factorial problem. Although significant progress has been made during the last decades in leukemia diagnosis and treatment, making new therapies available to Mexican patients is a priority, and cell and gene therapies are on the horizon. Efforts are ongoing to make CAR-T cell therapy accessible for patients in Mexico. This article summarizes a general landscape of childhood leukemias in Mexico, and we give a perspective about the current strategies, advances, and challenges ahead to make gene and cell therapies for leukemia clinically available.

show abstract

“…In 2018, the founding year of Fundación de Beneficencia Pública DKMS, 212 hematopoietic cell transplants performed in Chile were reported to the Latin American Blood and Marrow Transplantation Group (LABMT) activity survey, 50.9% thereof in an allogenic setting. In only 18.5% ( n =20) of these allogenic transplantations the donor was unrelated ( 14 ).…”

Section: Introductionmentioning

confidence: 99%

“…In the Latin American countries, HSCT activity has been continuously increasing in recent years, but transplant rates and proportion of allotransplants from HLA-matched unrelated donors are still substantially lower compared with that in North America and European regions. The lower HSCT activity is related to the economic resources of the respective countries, but also to the insufficient representation of regional HLA genotypes in the global donor pool (11)(12)(13)(14). In 2018, the founding year of Fundacioń de Beneficencia Publica DKMS, 212 hematopoietic cell transplants performed in Chile were reported to the Latin American Blood and Marrow Transplantation Group (LABMT) activity survey, 50.9% thereof in an allogenic setting.…”

Section: Introductionmentioning

confidence: 99%

HLA allele and haplotype frequencies of registered stem cell donors in Chile

Solloch,

Giani,

Pattillo Garnham

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Patients in need of hematopoietic stem cell transplantation often rely on unrelated stem cell donors matched in certain human leukocyte antigen (HLA) genes. Donor search is complicated by the extensive allelic variability of the HLA system. Therefore, large registries of potential donors are maintained in many countries worldwide. Population-specific HLA characteristics determine the registry benefits for patients and also the need for further regional donor recruitment. In this work, we analyzed HLA allele and haplotype frequencies of donors of DKMS Chile, the first Chilean donor registry, with self-assessed “non-Indigenous” (n=92,788) and “Mapuche” (n=1,993) ancestry. We identified HLA alleles that were distinctly more abundant in the Chilean subpopulations than in worldwide reference populations, four of them particularly characteristic for the Mapuche subpopulation, namely B*39:09g, B*35:09, DRB1*04:07g, and DRB1*16:02g. Both population subsamples carried haplotypes of both Native American and European origin at high frequencies, reflecting Chile’s complex history of admixture and immigration. Matching probability analysis revealed limited benefits for Chilean patients (both non-Indigenous and Mapuche) from donor registries of non-Chilean donors, thus indicating a need for ongoing significant donor recruitment efforts in Chile.

show abstract

Increasing access to hematopoietic cell transplantation in Latin America: results of the 2018 LABMT activity survey and trends since 2012

Cited by 12 publications

References 28 publications

Fostering next generation transplant physicians

Fostering next generation transplant physicians

Childhood leukemias in Mexico: towards implementing CAR-T cell therapy programs

HLA allele and haplotype frequencies of registered stem cell donors in Chile

Contact Info

Product

Resources

About